BioInsights - FectoVIR®-AAV, the new tool to enhance recombinant AAV production for gene therapy
Mar
24
2021
On demand

FectoVIR®-AAV, the new tool to enhance recombinant AAV production for gene therapy

Sponsor
FectoVIR®-AAV, the new tool to enhance recombinant AAV production for gene therapy

Ever-increasing demand for clinical and commercial-scale recombinant adeno-associated viral (rAAV) vector manufacturing has brought into sharp focus the need for new technological innovation to drive the requisite bioprocess productivity and efficiency gains.    

In this webinar, Viralgen - a CDMO born as a joint venture between Askbio and Columbus Venture Partners, and recently acquired by Bayer - will discuss its approach to driving the industrialization of rAAV vector production, and present recent data obtained with the FectoVIR®-AAV transfection reagent for the production of rAAV in its Pro10™ cell line.

Attendees will learn:

  • How to optimize AAV productions based on improved transfection tools.
  • How to improve transfection reproducilbility and rAAv production at different production scales.

Mathieu Porte

Bioproduction R&D Manager, Polyplus-transfection®

Mathieu Porte is Bioproduction R&D Manager at Polyplus-transfection®. After obtaining his Biotechnology Engineering Degree from the renowned European School ESBS (Strasbourg, France), he worked as Research Assistant at New England Biolabs and UCSF. He joined Polyplus-transfection® in 2009. During 10 years in the Bioproduction R&D group, he carried out the development of several innovative transfection solutions dedicated to biomanufacturing.

Valerie Lang

USP Manager, Viralgen VC

Valerie Lang is USP Manager at Viralgen Vector Core. She obtained her PhD in molecular and cellular pharmacology in the University of Pierre and Marie Curie (Paris, France). She has extensive experience in cell culture and manufacturing. She joined Viralgen in 2017 and has been responsible for designing, implementing, and optimizing industrial AAV processes and manufacturing.

Elisa Da Silva Ferrada

Upstream Process Development Lead Scientist, Viralgen VC

Elisa da Silva Ferrada is USP Process Development Lead Scientist at Viralgen Vector Core (VVC). Got her PhD at University of Basque Country in Molecular Biology and Biomedicine. Joined to VVC in 2019 to work on USP process development for AAV production


SPEAKERS

Mathieu Porte
Mathieu Porte
Project Leader at Polyplus-transfection
Elisa Da Silva Ferrada
Elisa Da Silva Ferrada
USP Process Development Lead Scientist, Viralgen Vector Core (VVC)
Valerie Lang
Valerie Lang
Production Manger, Viralgen VC

You might also like